FORA Capital LLC Buys Shares of 41,547 ADMA Biologics, Inc. (NASDAQ:ADMA)

FORA Capital LLC bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 41,547 shares of the biotechnology company's stock, valued at approximately $831,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of ADMA Biologics by 12.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 750,788 shares of the biotechnology company's stock valued at $15,008,000 after purchasing an additional 85,250 shares in the last quarter. FMR LLC boosted its position in shares of ADMA Biologics by 3.7% during the 3rd quarter. FMR LLC now owns 1,944,831 shares of the biotechnology company's stock valued at $38,877,000 after purchasing an additional 68,881 shares in the last quarter. Bank of Montreal Can boosted its position in shares of ADMA Biologics by 30.6% during the 3rd quarter. Bank of Montreal Can now owns 2,086,322 shares of the biotechnology company's stock valued at $40,443,000 after purchasing an additional 489,320 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of ADMA Biologics during the 3rd quarter valued at about $62,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 7.9 %

Shares of ADMA traded down $1.72 during midday trading on Friday, hitting $20.11. The stock had a trading volume of 4,002,265 shares, compared to its average volume of 3,622,850. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The business has a 50-day simple moving average of $19.08 and a two-hundred day simple moving average of $15.23. The firm has a market cap of $4.75 billion, a P/E ratio of 72.86 and a beta of 0.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. During the same period last year, the company posted $0.01 earnings per share. As a group, equities analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ADMA. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday, November 8th.

Insiders Place Their Bets

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.